Insight Molecular Diagnostics (0KCC) Ownership - Who Owns Insight Molecular Diagnostics?
Insight Molecular Diagnostics (0KCC) Ownership Overview
- 78.79% Insiders
- 2.85% Mutual Funds
- 2.80% Other Institutional Investors
- 2.33% ETFs
- 13.23% Public Companies and Individual Investors
The ownership structure of Insight Molecular Diagnostics (GB:0KCC) stock is a mix of institutional, retail, and individual investors. Approximately 7.98% of the company’s stock is owned by Institutional Investors, 78.79% is owned by Insiders, and 13.23% is owned by Public Companies and Individual Investors.
The ownership structure of Insight Molecular Diagnostics (GB:0KCC) stock is a mix of institutional, retail, and individual investors. Approximately 7.98% of the company’s stock is owned by Institutional Investors, 78.79% is owned by Insiders, and 13.23% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Apr 26, 2026 | Broadwood Partners Lp | $2,029,042 | |
| Apr 19, 2026 | Broadwood Partners Lp | $652,160 | |
| Feb 11, 2026 | Broadwood Partners Lp | $2,999,999 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Broadwood Partners Lp | 25,369,925 | Insider | 77.53% | 75,602,377 |
| Vanguard | 723,464 | Institution | 2.21% | 2,155,923 |
| Vanguard Index Funds | 723,464 | Institution | 2.21% | 2,155,923 |
| Andrea S. James | 206,060 | Insider | 0.63% | 614,059 |
| Fidelity Concord Street Trust | 195,056 | Institution | 0.60% | 581,267 |
| BlackRock, Inc. | 150,521 | Institution | 0.46% | 448,553 |
| Andrew Last | 58,752 | Insider | 0.18% | 175,081 |
| Lou Silverman | 55,807 | Insider | 0.17% | 166,305 |
| Andrew Arno | 52,447 | Insider | 0.16% | 156,292 |
| Ishares | 39,266 | Institution | 0.12% | 117,013 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 723,464 | Institution | 2.21% | 2,155,923 |
| Fidelity Concord Street Trust | 195,056 | Institution | 0.60% | 581,267 |
| Vanguard Valley Forge Funds | 7,927 | Institution | 0.02% | 23,622 |
| Vanguard Institutional Index Funds | 4,456 | Institution | 0.01% | 13,279 |
| Victory Portfolios Iii | 1,464 | Institution | <0.01% | 4,363 |
| John Hancock Variable Insurance Trust | 652 | Institution | <0.01% | 1,943 |
FAQ
Who Owns Insight Molecular Diagnostics (GB:0KCC)?
According to the latest TipRanks data, approximately 7.98% of the company's stock is held by institutional investors, 78.79% is held by insiders, and 13.23% is held by public companies and individual investors.
What percentage of Insight Molecular Diagnostics (GB:0KCC) stock is held by institutional investors?
According to the latest TipRanks data, approximately 7.98% of Insight Molecular Diagnostics (GB:0KCC) stock is held by institutional investors: 2.85% by mutual funds, 2.33% by ETFs and 2.80% by other institutional investors.
What percentage of Insight Molecular Diagnostics (GB:0KCC) stock is held by retail investors?
According to the latest TipRanks data, approximately 13.23% of Insight Molecular Diagnostics (GB:0KCC) stock is held by public companies and individual investors.
Who owns the most shares of Insight Molecular Diagnostics (GB:0KCC)?
Broadwood Partners Lp owns the most shares of Insight Molecular Diagnostics (GB:0KCC).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
